Psychedelics for Alzheimer's disease and stress-induced disorders under study at Columbia University

Silo Pharma Inc. SILO has agreed with Columbia University to extend the psychedelic biotechnology company's option to license certain treatments currently under development, including Alzheimer's and stress-induced anxiety.

The compounds evaluated in the Columbia study, whose early stages showed positive results, are two from Silo's proprietary pipeline: SPC-14, a new drug combining two approved therapies and targeting NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms of Alzheimer's disease and SPC-15, which uses ketamine compositions as a method of treating and preventing stress-induced affective disorders.

The agreement extension incorporates the work of Dr. Christine Ann Denny, associate professor of clinical neurobiology in psychiatry at Columbia University Irving Medical Center.

Dr. Denny and his team are focused on assessing the molecular mechanisms behind learning and memory, including diseases such as Alzheimer's disease, and whether ketamine and other new drugs can improve memory retrieval. , stop or even reverse the process of memory loss or cognitive aging.

The positive results of this study could have life-changing implications for people with conditions ranging from Alzheimer's disease to PTSD.

In the meantime, Silo is conducting concurrent research studies, including the joint venture with Zylo Therapeutics to develop a sustained-release dermal delivery system for ketamine or psilocybin for multiple health indications and a research agreement with the University of California to study the effect of psilocybin on blood inflammation targeting Parkinson's disease, chronic pain and bipolar disorder.

Photo courtesy of Commons and Pexels.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

CANNABIS BENZINGA CONFERENCE

Meet the biggest players in the cannabis industry and strike deals that will drive the industry forward.

Featuring live company presentations, insider panels and unparalleled access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet .

Join us September 13-14, 2022 at The Palmer House in Chicago, IL.